Kazia Therapeutics

Kazia Therapeutics is a company in Sydney, Australia, focused on oncology. It describes itself as advancing next-generation therapeutics that target multiple layers of cancer and immune control, with multi-modal platforms targeting tumor dormancy designed to overcome metastases, recurrence, and resistance in aggressive and immunotherapy-refractory cancers. Its therapeutic strategy is organized around three complementary oncology platforms: Paxalisib, a dual PI3K/mTOR inhibitor; a PD-L1 Protein Degrader Platform; and a SETDB1 Inhibitor Platform. The company states it is focused on challenging solid tumors including brain and breast cancers.

Kazia Therapeutics is described in Wikidata as a company in Sydney, Australia. On its official website, Kazia states that it is advancing next-generation therapeutics that target multiple layers of cancer and immune control, with multi-modal platforms targeting tumor dormancy designed to overcome metastases, recurrence, and resistance in aggressive and immunotherapy-refractory cancers. The company says it is focused on challenging solid tumors, including brain and breast cancers, where immunotherapy has historically delivered limited benefit, and that its strategy combines translational science with clinical development expertise. Its therapeutic strategy is centered on three complementary oncology platforms: Paxalisib, a brain-penetrant oral dual PI3K/mTOR inhibitor with origins in neuro-oncology; a PD-L1 Protein Degrader Platform whose lead asset NDL2 is designed to selectively engage tumor-associated nuclear PD-L1 protein; and a SETDB1 Inhibitor Platform whose lead asset MSETC is designed to selectively target pathogenic SETDB1 complexes.

Next-generation precision oncology focused on reprogramming the tumor microenvironment to overcome immune resistance and treatment resistance in difficult-to-treat solid tumors.

• Paxalisib

  A brain-penetrant, oral, once-daily small molecule that acts as a dual PI3K/mTOR inhibitor, targeting key pathways that drive tumor growth and survival; it also influences tumor epigenetic regulation, transcriptional state, and the immune microenvironment. Described as having origins in neuro-oncology and advanced across multiple solid tumor indications.

• PD-L1 Protein Degrader Platform

  A first-in-class strategy to target unique tumor-specific nuclear PD-L1 post-translational forms not found in healthy cells; the target was identified through a reverse-translation liquid-biopsy profiling AI platform. Lead asset NDL2 is designed to selectively engage tumor-associated nuclear PD-L1 protein while sparing normal cellular PD-L1.

• SETDB1 Inhibitor Platform

  A first-in-class approach focused on disease-associated SETDB1 biology, an emerging driver of immune evasion, treatment resistance, and metastasis. Lead asset MSETC is designed to selectively target pathogenic SETDB1 complexes while sparing normal cellular function.

• 2021.12.13

  Reported2021.12.13

  Kazia Therapeutics appoints Karen Krumeich as CFO[6]Kazia Therapeutics任命Karen Krumeich为首席财务官prnewswire.com

  Kazia Therapeutics appointed Karen Krumeich as chief financial officer. She was expected to formally join the company in January 2022.

Read more

1. 1Kazia Therapeutics (KZIA)kaziatx.com
2. 2About Us :: Kazia Therapeutics (KZIA)kaziatx.com
3. 3Technology :: Kazia Therapeutics (KZIA)kaziatx.com
4. 4Paxalisib :: Kazia Therapeutics (KZIA)kaziatx.com
5. 5Kazia Therapeutics (Australia)wikidata.org
6. 6Kazia Therapeutics任命Karen Krumeich为首席财务官prnewswire.com
7. 7Kazia Therapeutics appoints US-based CFO to assist global market expansionproactiveinvestors.com.au